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Abstract 
Lithium is an effective treatment in pregnancy and postpartum for the prevention of relapse in bipolar disorder. How-
ever, lithium has also been associated with risks during pregnancy for both the mother and the unborn child. Recent 
large studies have confirmed the association between first trimester lithium exposure and an increased risk of con-
genital malformations. Importantly, the risk estimates from these studies are lower than previously reported. Tapering 
of lithium during the first trimester could be considered but should be weighed against the risks of relapse. There 
seems to be no association between lithium use and pregnancy or delivery related outcomes, but more research is 
needed to be more conclusive. When lithium is prescribed during pregnancy, lithium blood levels should be moni-
tored more frequently than outside of pregnancy and preferably weekly in the third trimester. We recommend a 
high-resolution ultrasound with fetal anomaly scanning at 20 weeks. Ideally, delivery should take place in a specialised 
hospital where psychiatric and obstetric care for the mother is provided and neonatal evaluation and monitoring of 
the child can take place immediately after birth. When lithium is discontinued during pregnancy, lithium could be 
restarted immediately after delivery as strategy for relapse prevention postpartum. Given the very high risk of relapse 
in the postpartum period, a high target therapeutic lithium level is recommended. Most clinical guidelines discourage 
breastfeeding in women treated with lithium. It is highly important that clinicians inform and advise women about 
the risks and benefits of remaining on lithium in pregnancy, if possible preconceptionally. In this narrative review we 
provide an up-to-date overview of the literature on lithium use during pregnancy and after delivery leading to clinical 
recommendations.
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Background
Lithium therapy has a well-established evidence base as 
a long-term maintenance treatment for bipolar disorder 
with demonstrated efficacy in reducing both manic and 
depressive relapse and anti-suicidal properties (Geddes 
and Miklowitz 2013). Bipolar disorder often has its onset 
before the age of 25 years (Merikangas et al. 2011), and as 
such lithium is frequently prescribed to women of child-
bearing age. However, there is enormous global variance 
in prescription patterns of lithium and recommendations 
for its use during the perinatal period (defined as preg-
nancy and the first year postpartum). In general, data 
on the prevalence of lithium use during pregnancy are 
scarce with the exception of population-based studies 
from Denmark and the UK. In a recent clinical overview, 
the Danish author Larsen and colleagues recommended 
lithium as the first-line mood-stabilizing treatment dur-
ing pregnancy (Larsen et  al. 2015). Despite this recom-
mendation, only 16% (53/336) of women with bipolar 
disorder redeemed at least one lithium prescription dur-
ing pregnancy and only 6.3% of women used lithium in 
the third trimester, indicating that the majority of women 
discontinued lithium during pregnancy (Broeks et  al. 
2017). Similarly, in the UK discontinuation rates of lith-
ium during pregnancy is high with a study of pregnant 
women showing that only 17 out of 52 pregnant women 
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continued lithium use during pregnancy (McCrea et  al. 
2015). This pattern of discontinuation of lithium before 
pregnancy is supported by the NICE guideline where it 
is recommended to “not offer lithium to women who are 
planning a pregnancy or pregnant, unless antipsychotic 
medication has not been effective” (National Collaborat-
ing Centre for Mental H 2014). For most other countries 
information on lithium use during pregnancy is lacking. 
In a recent meta-analysis on bipolar disorder in the peri-
natal period, 5700 bipolar pregnancies (n = 37 studies) 
were included (Wesseloo et al. 2016). Of these, informa-
tion on medication use was only available for 445 bipolar 
pregnancies (60 women with various medication includ-
ing lithium and 385 women without medication). Most 
of these lithium users came from the Netherlands, which 
can be explained by the recommendation in the Dutch 
guidelines to list lithium as a first line treatment option 
during pregnancy (Trimbos-instituut 2015). In the Aus-
tralian Clinical Practice Guideline on perinatal mental 
health, no specific recommendation was made to con-
tinue or discontinue lithium during pregnancy, but rather 
proposes care pathways for both situations (Austin et al. 
2017). Altogether, guidelines give inconsistent and highly 
variable information regarding the safety of lithium use 
during pregnancy. A comprehensive Canadian review 
of recommendations for the treatment of bipolar disor-
der during pregnancy recommended: “Women at risk 
for new onset or relapse of a mood episode who are not 
on maintenance treatment should be considered for trial 
of a mood stabilizer other than valproate, or an atypical 
antipsychotic drug” (Sharma and Sharma 2016).
To guide clinicians in their decision making we provide 
a narrative review of the literature on efficacy of lithium 




To date the literature on the impact of pregnancy on 
the course of bipolar disorders is inconsistent. Previ-
ous studies suggested that women with bipolar disor-
der may have a lower risk of relapse during pregnancy, 
when compared to the period before or after (Grof et al. 
2000). A recent systematic review concluded that based 
on the literature to date the question of how pregnancy 
affects the course of bipolar disorder can’t be answered 
(Salim et al. 2018). Viguera et al. showed that in women 
who discontinued mood stabilizing treatment including 
lithium during pregnancy (n = 62), the relapse risk was 
two times increased compared to women who continued 
treatment (n = 27) (Viguera et  al. 2007). In the postpar-
tum period there is a high risk of a bipolar episode and 
hospitalization for psychiatric morbidity (Munk-Olsen 
et  al. 2006; Harlow et  al. 2007; Di Florio et  al. 2013). A 
perinatal history of affective psychosis or depression is 
the most important risk factor, as reported in a recent 
cohort study investigating risk factors for postpartum 
recurrence in bipolar disorder (Di Florio et  al. 2018). 
Unfortunately, this study did not investigate the effect of 
medication use during pregnancy on the risk of recur-
rence. A recent meta-analysis showed significantly higher 
postpartum relapse rates in women without medication 
during pregnancy (N = 385; 66%, 95% CI 57–75) as com-
pared to women using prophylactic medication (N = 60, 
23%, 95% CI 14–37) (Wesseloo et al. 2016). Of these 60 
patients with prophylactic medication during pregnancy, 
the majority used lithium (Bergink et  al. 2012; Austin 
1992; Freeman et  al. 2002; Bilszta et  al. 2010). Hence, 
lithium prophylaxis during pregnancy in women with 
bipolar disorder might be important not only to maintain 
mood stability during pregnancy, but also for postpartum 
relapse prevention.
Interestingly, a recent population based cohort study 
reported that lamotrigine during pregnancy was not infe-
rior to lithium in the prevention of severe postpartum 
episodes (Wesseloo et  al. 2017). However, the authors 
point out the likely influence of confounding by indi-
cation since lamotrigine was primarily prescribed to 
women with a vulnerability for depressive episodes, while 
lithium was primarily prescribed to women with a his-
tory of manic episodes. Therefore, this finding requires 
replication in studies that can account for diagnosis, vari-
ant and severity of illness.
Dosing and monitoring of blood levels during pregnancy 
and around delivery
Lithium has a narrow therapeutic range of 0.5–
1.2 mmol/L and higher levels may lead to toxicity (Oruch 
et  al. 2014). Excretion of lithium is almost exclusively 
renal, hence blood plasma levels mainly depend on intra-
vascular volume and glomerular filtration rate (GRF) 
(Oruch et al. 2014; Grandjean and Aubry 2009). As preg-
nancy progresses total body water, plasma volume and 
GFR are increased (Pariente et al. 2016) with GFR rising 
from as early as 6 weeks gestation up to 50% over non-
pregnant women by the end of the first trimester (Davi-
son 1984). Clinical studies have shown lithium blood 
levels to decrease significantly during pregnancy (Wes-
seloo et al. 2017; Westin et al. 2017). An average decrease 
of 24% in the first trimester, 36% in second trimester and 
21% in third trimester was described. Creatinine blood 
levels showed a similar longitudinal pattern, showing that 
indeed changes in lithium blood level reflect changes in 
renal physiology.
In summary, first and second trimester are charac-
terised by a significant decrease of lithium blood levels 
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with a risk of subtherapeutic levels. In third trimester 
and the postpartum, lithium levels gradually return to 
their preconception level which implicates that in this 
period clinicians need to be aware of the risk of lith-
ium intoxication. Close monitoring and dose adjust-
ment is needed with conditions such as hyperemesis 
gravidarum, pre-eclampsia, impaired renal function, 
concomitant medication or acute blood loss occur, as 
these conditions increased the risk of toxicity (Han-
dler 2009; Blake et  al. 2008). Furthermore, as lithium 
levels in the fetus equal those in the mother, changes 
in dosing may impact fetal health and increase the risk 
of complications (Newport et al. 2005). A multiple day 
dosing regime has been proposed to minimise fetal risk 
by minimising peak lithium levels (Horton et al. 2012). 
However, multiple day dosing has been associated with 
an increased risk of renal side effects and as a conse-
quence possible non-adherence (Singh et  al. 2011). 
Therefore, twice daily dosing seems to be preferred to 
more frequent administration.
The above described dynamic changes in GFR and 
maternal haemodynamics during pregnancy necessi-
tate monthly monitoring of lithium blood levels until 
34 weeks and weekly monitoring thereafter until deliv-
ery (Wesseloo et al. 2017).
Several authors and guidelines have suggested to 
decrease or discontinue lithium treatment when in 
labour in order to minimise lithium side-effects in the 
neonate (National Collaborating Centre for Mental H 
2014; Trimbos-instituut 2015; Newport et  al. 2005). 
However, there is currently no evidence that suggests 
this strategy decreases the risk of perinatal and infant 
complications and this strategy has to be weighed 
against the risk of maternal relapse during a high-risk 
period. Both Deligiannidis et  al. and Wesseloo et  al. 
have recommended careful lithium blood level moni-
toring instead of discontinuation in all cases (Deli-
giannidis et  al. 2014). Lithium blood levels should be 
measured before and 24  h after delivery and adequate 
fluid management is important to prevent dehydration. 
Lithium blood level, as well as thyroid-stimulating hor-
mone (TSH) and free thyroxine (T4) should be evalu-
ated in umbilical cord blood sample (Trimbos-instituut 
2015). Nephrotoxic medication and nonsteroidal anti-
inflammatory drugs should be avoided (Deligiannidis 
et  al. 2014). When considering anaesthesia options 
during delivery, drug interactions with lithium should 
be taken into account. Lithium potentiates succinylcho-
line and pancuronium and can be expected to poten-
tiate other depolarising and non-depolarizing muscle 
relaxants (Blake et al. 2008). Close monitoring of neu-
romuscular function is therefore required. Regional 
anaesthesia is considered to be safe (Blake et al. 2008).
Obstetric complications
When investigating the effect of lithium exposure on 
obstetric complications in cohort studies it is impor-
tant to consider that bipolar disorder, the indication 
for which lithium is often prescribed, is associated with 
obstetric complications independent of medication. In 
specific, women with bipolar disorder are at increased 
risk of antepartum hemorrhage, placental abnormali-
ties and caesarean section (Boden et al. 2012; Jablensky 
et  al. 2005). The mechanism underlying this increased 
risk for women with bipolar disorder is unclear but 
psychosocial stress accompanied by high cortisol lev-
els, comorbidity and lifestyle factors might play a role 
(Boden et  al. 2012). In a recent shared protocol meta-
analysis of 727 lithium exposed pregnancies and 21,397 
pregnancies in disease matched controls lithium use 
during pregnancy was not associated with preeclamp-
sia, diabetes during pregnancy, fetal distress, postpar-
tum hemorrhage or caesarean section (Munk-Olsen 
et  al. 2018). Additionally, in two studies the rates of 
obstetric complications were not higher in women 
who continued lithium during pregnancy compared 
to women who discontinued lithium before or early 
in pregnancy (Petersen et al. 2016; Frayne et al. 2017). 
Table 1 presents an overview of the results from obser-
vational cohort studies on obstetric complications of 
lithium use during pregnancy. Results of these studies 
should be interpreted considering several methodologi-
cal limitations, i.e. the sample size of two studies was 
very small and these studies did not correct for con-
founding variables and timing, duration or dose of the 
exposure.
Polyhydramnios has not been investigated in obser-
vational cohort studies, but has been described in 
two case reports (Ang et  al. 1990; Krause et  al. 1990). 
This warrants further investigation because polyuria 
is a well-known side effect of lithium and fetal polyu-
ria could lead to polyhydramnios. In summary, while 
women with bipolar disorder have an increased risk 
of obstetric complications, there seems no association 
between lithium use during pregnancy and pregnancy 
or delivery related outcomes.
Consequences for the developing child
Lithium freely crosses the placental barrier and lith-
ium concentrations equilibrate between maternal and 
fetal circulation (Newport et al. 2005). Hence maternal 
lithium therapy results in fetal lithium exposure. We 
provide a summary of published results from investi-
gations on the short- and long-term consequences of 
intrauterine exposure to lithium.
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Congenital malformations
The first trimester of pregnancy is crucial to the nor-
mal development of the fetus. Since in this period all 
major body organs are forming, the fetus is susceptible 
to damage from teratogens and this has raised some 
concerns about the possible teratogenicity of lithium 
use during the first trimester. In this review we summa-
rise the results from clinical cohort studies investigat-
ing the risk of congenital malformations after lithium 
use during pregnancy, an overview of these studies is 
presented in Table 2.
In multiple investigations, lithium treatment dur-
ing pregnancy has been associated with cardiovascular 
malformations, including Ebstein anomaly (Weinstein 
and Goldfield 1975; Schou et  al. 1973; Nora et  al. 1974; 
Patorno et  al. 2017). Ebstein anomaly is a congenital 
malformation characterised by an abnormal develop-
ment of the tricuspid valve and the right ventricle, with 
highly variable prognosis. The prevalence in the normal 
population is estimated to be about 1 per 20,000 live 
births (Lupo et  al. 2011). The association with lithium 
use during pregnancy was first reported in the 1970s 
investigation on the Register of Lithium Babies (Wein-
stein and Goldfield 1975; Schou et  al. 1973). Based on 
the data from the Register of Lithium Babies, Nora et al. 
estimated a fivefold increase in the risk of congenital 
heart-disease and about a 400-fold increase in the risk 
of Ebstein anomaly (Nora et  al. 1974). In contrast, case 
control studies in children born with Ebstein anomaly or 
other cardiovascular malformations did not find an asso-
ciation with lithium exposure (Zalzstein et al. 1990; Boyle 
et al. 2016; McKnight et al. 2012; Correa-Villasenor et al. 
1994; Sipek 1989; Lisi et  al. 2010). For a comprehensive 
summary of case–control studies we refer to a review and 
meta-analysis by McKnight et al. (2012). A registry based 
case control study of 264 Ebstein anomaly cases by Boyle 
et  al. found an association with maternal mental health 
problems in general but not with lithium use (Boyle et al. 
2016).
Two studies on congenital malformations in general 
have yielded contradicting results, with one study report-
ing a high rate of congenital malformations after in utero 
exposure to lithium (Reis and Kallen 2008) and another 
study reporting no association between lithium expo-
sure and congenital malformations (Jacobson et al. 1992). 
Additionally, several case reports have been published on 
congenital diaphragmatic hernia (Hosseini et  al. 2010), 
goiter (Frassetto et al. 2002; Nars and Girard 1977), car-
diovascular complications (Park et  al. 1980; Long and 
Willis 1984; Arnon et al. 1981; Wilson et al. 1983), bilat-
eral hip dislocation (Deiana et al. 2014) and neural-tube 
defect (Jacobson et al. 1992). In general, sample sizes of 
these clinical investigations are considered too small to 
study rare congenital malformations.
Recently, three cohort studies with large sample sizes, 
have provided more evidence on the matter (Munk-Olsen 
et  al. 2018; Patorno et  al. 2017; Diav-Citrin et  al. 2014). 
Diav-Citrin et al. compared the rate of congenital abnor-
malities in lithium exposed pregnancies, disease matched 
and nonteratogenic-exposed pregnancies (Diav-Citrin 
et al. 2014). The occurrence of cardiovascular anomalies 
was higher in the lithium-exposed group although this 
difference was not significant after excluding the anoma-
lies that resolved spontaneously. Patorno et al. used reg-
ister data from Medicaid in the U.S. to study 1,325,563 
pregnancies of which 663 were exposed to lithium and 
1945 exposed to lamotrigine (Patorno et al. 2017). They 
found a dose dependent association between lithium 
exposure and cardiac malformations, including Ebstein 
anomaly. The adjusted risk ratio for cardiac malforma-
tions was calculated to be 1.65 compared to controls and 
2.25 compared to lamotrigine-exposed. The risk of car-
diac malformations was estimated to be in the order of 
one additional case per 100 live births. The same study 
Table 1 Obstetric outcome after lithium treatment during pregnancy: findings from clinical cohort studies
OR odds ratio, CI confidence interval
Study Design Sample size Findings
Petersen et al. (2016) Registry-based study Exposed = 35
Disease matched non-exposed = 84
Controls = 320.853
No difference in the rate of caesarean sections
Frayne et al. (2017) Cohort study Exposed = 33 No difference in the rate of obstetric complications 
between the women that continued (n = 19) or 
discontinued (n = 14) lithium
Munk-Olsen et al. (2018) Meta-analysis (six study sites) Exposed = 727
Disease matched controls = 21,397
No association between lithium exposure in utero and 
preeclampsia (OR 0.97, 95% CI 0.52–1.80), gestational 
diabetes (OR 1.20, 95% CI 0.81–1.78), fetal distress 
(OR 1.00, 95% CI 0.76–1.32), postpartum hemorrhage 
(OR 1.28, 95% CI 0.64–2.57) and caesarean section 
(OR 0.94, 95% CI 0.66–1.33)
Page 5 of 12Poels et al. Int J Bipolar Disord            (2018) 6:26 
found no association between lithium exposure and non-
cardiac malformations. In contrast, in a shared-protocol 
meta-analysis of six study sites the risk of major malfor-
mations (including cardiac malformations) was increased 
in lithium-exposed pregnancies (OR 1.62, 95% CI 1.12–
2.33) compared to non-exposed pregnancies in mothers 
with a mood disorder, while there was no statistically 
significant increase in the risk of cardiac malformations 
(Munk-Olsen et al. 2018).
While this evidence is not conclusive it is recom-
mended that it is discussed with women who seek advice 
on treatment of bipolar disorder either pre-pregnancy or 
during pregnancy. One option would be to taper lithium 
during the first trimester although the risk of relapse 
needs to weighed if considering this option. In the case 
of lithium continuation, fetal anomaly ultrasound includ-
ing detailed fetal cardiac scanning, should be offered at 
20  weeks gestational age. This could also be advised at 
16 weeks (Galbally et al. 2010). In the case of detection of 
a cardiac malformation, information, guidance and coun-
selling can be offered as early as possible. Although the 
pathophysiology of the association between lithium and 
congenital malformations is unclear, it might be related 
to lithium’s inhibition of the glycogen synthase kinase-3β 
(GSK3β) (Young 2009). GSK3β expression is of impor-
tance for the Wnt signaling pathway, which is of influ-
ence on cardiac and vascular development in the embryo 
(Corada et al. 2010; Jope 2003).
Neonatal outcomes
Two studies found an increased risk of preterm birth in 
women with lithium use during pregnancy when com-
pared to controls (Diav-Citrin et  al. 2014; Troyer et  al. 
1993). In contrast, three studies including the meta-anal-
ysis of six studies reported no difference in the rate of 
preterm birth between lithium exposed pregnancies and 
controls (Newport et  al. 2005; Munk-Olsen et  al. 2018; 
Jacobson et  al. 1992). In addition, most studies do not 
Table 2 Findings from  clinical cohort investigations on  the  association between  in  utero exposure to  lithium 
and congenital malformations
RR risk ratio, OR odds ratio, CI confidence interval
Study Design Sample size Findings
Schou et al. (1973) Cohort study Exposed = 118 Nine children with congenital malforma-
tions, of which six with cardiovascular 
malformations
Nora et al. (1974) Retrospective cohort study Teratogenic history obtained in 733 
women
Two lithium exposed pregnancies and both 
children were born with Ebstein anomaly
Weinstein and Goldfield (1975) Cohort study Exposed = 143 Cardiovascular abnormalities found in 9.1% 
of cases of exposure to lithium in 1st 
trimester
Kallen and Tandberg (1983) Registry-based study Exposed = 59
Other drugs = 38
Disease matched non-exposed = 80
Controls = 110
Four children with heart defects after 
lithium exposure. No cases of Ebstein 
anomaly
Jacobson et al. (1992) Prospective cohort study Exposed = 138
Controls = 148
No difference in the rate of major malfor-
mations
Reis and Kallen (2008) Registry-based study Exposed = 79 Eight children with congenital malfor-
mations, of which four with cardiac 
malformations
Diav-citrin et al. (2014) Prospective cohort study Exposed = 183
Disease matched non-exposed = 72
Controls = 748
Single center comparison: no difference 
in major malformations, increased risk of 
cardiovascular malformations (RR 7.23, 
95% CI 1.97–26.53), not after excluding 
cases that spontaneously resolved (RR 
5.78, 95% CI 0.82–40.65)
Patorno et al. (2017) Registry-based study Exposed = 663
Lamotrigine = 1945
Controls = 1,322,955
Increased risk of cardiac malformations after 
first trimester lithium exposure compared 
to controls (RR 1.65, 95% CI 1.02–2.68) 
and lamotrigine-exposed (RR 2.25, 95% CI 
1.17–4.34)
Munk-Olsen et al. (2018) Meta-analysis (six study sites) Exposed = 727
Disease matched controls = 21,397
First trimester lithium exposure was 
statistically significant associated with 
congenital malformations (OR 1.62, 
95% CI 1.12–2.33) but not with cardiac 
malformations in specific (OR 1.54, 95% CI 
0.64–3.70)
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find differences in birth weight except for one small study 
in which lithium-exposed neonates had a higher birth 
weight (Newport et  al. 2005; Munk-Olsen et  al. 2018; 
Jacobson et al. 1992; Diav-Citrin et al. 2014; Troyer et al. 
1993).
Lithium exposure is associated with increased risk of 
neonatal complications. Newport et  al. found an asso-
ciation between high infant lithium concentrations and 
lower 1-min Apgar scores, higher rate of central nerv-
ous system and neuromuscular complications and longer 
duration of hospital stays (Newport et  al. 2005). In a 
cohort of 19 babies exposed to lithium during pregnancy, 
8 were admitted to a special care unit post-delivery 
(Frayne et  al. 2017). This high rate of neonatal admis-
sions was confirmed in a large meta-analysis of six study 
sites (Munk-Olsen et  al. 2018). Additionally, there are 
case reports on neonatal lithium toxicity (Kozma 2005; 
Flaherty and Krenzelok 1997; Morrell et al. 1983; Woody 
et  al. 1971; Wilbanks et  al. 1970; Stothers et  al. 1973), 
nephrogenic diabetes insipidus (Pinelli et  al. 2002), and 
jaundice (Connoley and Menahem 1990). In a review of 
case reports, Kozma further reports respiratory prob-
lems, hypotonia, lethargy, poor drinking ability, thyroid 
problems, cyanosis, hypoglycemia and polyuria (Kozma 
2005). Normal neonatal outcome was reported in the 
study from Silverman et al. (1971).
Because of potential problems in the neonatal period 
after in utero exposure to lithium, we recommend that 
delivery should take place in a specialised hospital with 
advanced neonatal care available immediately after 
delivery. In Table  3 we present the results of studies on 
neonatal outcome.
Long term developmental outcome
It is assumed that the fetal environment influences life-
time disease risk based on Barker’s hypothesis of Devel-
opmental Origins of Health and Disease (DOHaD) 
(Barker 1990; Schlotz and Phillips 2009). This hypoth-
esis proposes that exposure during fetal development 
can result in permanent physiological and metabolic 
changes, which modify disease risk through life. Prenatal 
exposure to lithium may therefore have consequences on 
development and health outcomes well beyond infancy. 
Indeed, results from preclinical studies in mice, rats and 
zebrafish show neurodevelopmental deficits (Poels et al. 
2018). Clinical data are scarce, four small clinical cohort 
studies have investigated long term neurodevelopmental 
outcomes. The results of these studies are presented in 
Table  4. Schou used data from the Scandinavian Regis-
ter of Lithium Babies to compare the mothers’ subjective 
retrospective assessment of their children’s development 
in lithium-exposed children (n = 60) and their non-
exposed siblings (n = 57) and found no difference (Schou 
1976). In a prospective multicenter study, there was no 
difference in the age of attainment of major developmen-
tal milestones in lithium-exposed children compared to 
non-exposed children (Jacobson et  al. 1992). Another 
study examined 15 lithium-exposed children at the age 
of 3–15  years old and used standard validated tests to 
assess growth, neurological, cognitive and behavioural 
Table 3 Neonatal outcome after lithium treatment during pregnancy: findings from clinical cohort studies
OR odds ratio, CI confidence interval
Study Design Sample size Findings
Jacobson et al. (1992) Prospective cohort study Exposed = 138
Controls = 148
No difference in the rate of preterm birth
Higher birthweight in lithium exposed neonates
Troyer et al. (1993) Cohort study Exposed = 60
Disease matched non-exposed = 290
Cohort of manic-depressive women: risk ratio for 
prematurity of 2.54
No difference in birthweight
Newport et al. (2005a, b) Cohort study Exposed = 24 Lower Apgar scores, longer hospital stays and higher 
rates of CNS and neuromuscular complications in 
infants with high lithium levels
No statistically significant association with preterm 
birth or low birth weight
Diav-citrin et al. (2014) Prospective cohort study Exposed = 183
Disease matched non-exposed = 72
Controls = 748
2.3 times higher rate of preterm delivery in exposed 
group (13.7% versus 6.0%)
No differences in birth weight
Frayne et al. 2017 Cohort study Exposed = 19 Eight neonates admitted to a special care unit
Munk-Olsen et al. (2018) Meta-analysis (six study sites) Exposed = 727
Disease matched controls = 21,397
No association between lithium exposure in utero 
and preterm birth (OR 1.24, 95% CI 0.83–1.84), low 
birth weight (OR 0.98, 95% CI 0.72–1.35) or small for 
gestational age (OR 0.90, 95% CI 0.67–1.21)
A significant higher rate of neonatal admission
(OR 1.62, 95% CI 1.12–2.33)
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outcomes (van der Lugt et al. 2012). Most children scored 
lower on the performance Block patterns when com-
pared to the general population although this difference 
was not statistically significant. Growth and behavioural 
development was within normal range. One child in this 
study was diagnosed with minor neurological dysfunc-
tion without clinical implications. A recent study com-
pared the intelligence quotient (IQ) in children with in 
utero exposure to lithium (n = 20), non-exposed children 
of mothers with a mood disorder (n = 8) and controls 
(n = 11) and reported no difference in total, performance 
or verbal IQ (Forsberg et al. 2017).
In summary, while preclinical evidence does point to 
possible developmental effects of perinatal exposure to 
lithium, this is not found in clinical investigations. Due 
to methodological weaknesses of the published clini-
cal studies (e.g. small sample sizes, lack of control group 
and subjective outcome measures) no conclusion can be 
drawn from these results and more research is needed to 
provide an estimation of the risk for the developing child.
Lithium use during pregnancy
• Maintenance of lithium during pregnancy is effective 
in the prevention of relapse during pregnancy and 
the postpartum period.
• The first and second trimester are characterized by a 
significant decrease in blood levels for lithium.
• Fetal anomaly ultrasound including detailed fetal car-
diac scanning, should be offered at 20  weeks gesta-
tional age.
• In the third trimester, weekly monitoring of lithium 
blood levels is recommended. Preferably, lithium 
blood levels should be measured before and 24  h 
after delivery.
• Lithium blood level, TSH and free T4 should be eval-
uated in umbilical cord blood sample.
• Lithium use during pregnancy has not been associ-
ated with obstetric complications. However, the asso-
ciation with preterm birth and birthweight remains 
uncertain.
• Lithium exposure during the first trimester is associ-
ated with congenital malformations in several stud-
ies, recent studies estimate the risk lower than pre-
viously reported. Tapering of lithium during the first 
trimester should be considered but weighed against 
the risks of relapse.
• Lithium exposure is associated with increased risk of 
neonatal complications. Lithium-exposed neonates 
should be observed directly post-delivery.
• Little is known about the developmental conse-
quences of intrauterine exposure to lithium.
Lithium use postpartum
Efficacy
Women with a history of bipolar disorder or postpartum 
psychosis are at extremely high risk of relapse postpar-
tum. Few clinical studies have investigated the efficacy 
of pharmacotherapy when it is initiated immediately 
after delivery, as a prophylactic strategy in women who 
have not been treated during pregnancy. A meta-analysis 
showed that patients with bipolar disorder using prophy-
lactic pharmacotherapy during the postpartum period 
had a lower relapse rate (N = 98; 29%, 95% CI 16–47) 
compared with those who remained medication free 
(N = 107; 65%, 95% CI 55–73) (Wesseloo et  al. 2016). 
Off these 98 women, 38 started prophylactic treatment 
during pregnancy while 22 were medication free dur-
ing pregnancy and initiated prophylaxis immediately 
Table 4 Neurodevelopmental consequences of intrauterine exposure to lithium: findings from clinical cohort studies
IQ intelligence quotient, n.r. not reported
Study Design Sample size Follow-up Findings
Schou (1976) Prospective cohort study Exposed = 60
Controls = 57
Mean = 7 years No difference in development based on ques-
tionnaire filled out by the mother
Jacobson et al. (1992) Prospective cohort study Exposed = 22
Controls = n.r.
1–9 years, mean = 61 weeks No difference in attainment of milestones
van der Lugt et al. (2012) Cohort study Exposed = 15 3–15 years Normal developmental milestones (n = 15), 
minor neurological dysfunction (n = 1), low 
verbal + total IQ, normal performance IQ 
(n = 1), subclinical anxiety problems (n = 2), 
subclinical oppositional problems (n = 1)





4–5 years No differences in total, performance and verbal 
IQ
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postpartum. For the remaining women information 
regarding the timing was unavailable or they were on 
chronic maintenance treatment. Numbers are very small 
but in all studies on prophylactic treatment with lith-
ium postpartum, women with bipolar disorder had sig-
nificantly lower rates of postpartum relapse compared 
to medication free women (Bergink et  al. 2012; Austin 
1992; Cohen et al. 1995). In contrast, valproate failed to 
demonstrate significant prophylactic benefits (Wisner 
et  al. 2004) and further investigation of second genera-
tion antipsychotics is warranted. In our previous work 
we have recommended distinct perinatal treatment algo-
rithms for women with bipolar disorder and women with 
a history of psychosis limited to the postpartum period. 
In women with bipolar disorder, prophylaxis during 
pregnancy increases the likelihood of maintaining mood 
stability during pregnancy and preventing postpartum 
relapse. In women with a history of psychosis limited to 
the postpartum period, prophylactic treatment imme-
diately after birth is appropriate (Bergink et al. 2016). In 
this group of women with a history of postpartum psy-
chosis, the established efficacy of lithium makes it the 
drug of first choice for postpartum prophylaxis.
Dosing and monitoring of blood level
Lithium prophylaxis has demonstrated efficacy in reduc-
ing postpartum episodes. However, the dosing and 
duration of prophylaxis is unknown. We recommend 
relapse prevention prophylaxis in women with bipolar 
disorder with a higher lithium target level (for example 
0.8  mmol/L) during the first month postpartum. Given 
that the relapse risk is high particularly in the first month 
postpartum, we follow the view that the benefits of 
higher lithium target blood levels in the first month post-
partum outweighs the potential risks. We recommend to 
start lithium on the first evening after delivery and with a 
dose to target blood level of 0.8–1.0 mmol/L to optimize 
relapse prevention. In our previous work, we observed 
that normalization of renal function can take up to a few 
weeks after delivery as both mean lithium and creatinine 
blood levels were higher in the postpartum period than 
in the preconception period (+  9% and +  7% respec-
tively) (Wesseloo et al. 2017). Therefore, we recommend 
twice weekly monitoring of lithium blood levels for the 
first 2 weeks postpartum. Women with bipolar disorder 
on maintenance treatment with lithium might want to 
change to their preconception dose and blood level after 
1  month postpartum. For those women who want to 
taper their lithium dose (i.e. women with isolated post-
partum psychosis/mania in history, or women with bipo-
lar disorder without regular maintenance treatment) we 
advise to commence tapering after 3 months postpartum.
Breastfeeding
Clinical guidelines generally discourage breastfeeding in 
women treated with lithium due to the possible risk of 
lithium toxicity in the newborn (National Collaborating 
Centre for Mental H 2014). Furthermore, the lack of con-
tinued sleep during puerperium might also increase the 
risk of maternal relapse. Lithium is excreted into breast 
milk and the elimination rate in infants is lower than in 
adults, which may cause higher exposure levels in infants. 
However, there is a lack of data from clinical investiga-
tions on this topic. In Table  5 we present the results of 
clinical studies on infant lithium exposure through lac-
tation. Some case studies have estimated serum lithium 
levels to be about one-half of maternal serum lithium 
levels (Frew 2015; Schou and Amdisen 1973) while oth-
ers estimated levels closer to one quarter of the mothers’ 
levels (Bogen et  al. 2012; Sykes et  al. 1976). The larger 
study available for lithium and breastfeeding consists of 
11 mother infant pairs with a calculated infant lithium 
dose as 0–30% of the maternal dose per kilogram body-
weight, based on the daily milk intake and lithium levels 
measured in breast milk (Moretti et  al. 2003). Unfortu-
nately, serum lithium levels were only available in two 
Table 5 Summary of the results from clinical studies on infant lithium exposure through lactation
Study Design Sample size Findings
Schou et al. (1973) Case series 8 mother–infant pairs Infant/maternal serum lithium concentration of 1/2 in first week and 1/3 during the 
following weeks
Sykes et al. (1976) Case report 1 mother–infant pair Breast milk lithium level of 1/4 of maternal serum level, infant had good excretion of 
lithium into urine
Moretti et al. (2003) Case series 11 mother–infant pairs Infant lithium dose of 0–30% of the maternal dose/kg
Infant serum level of 17–50% of maternal serum level
Viguera et al. (2007a, b) Case series 10 mother–infant pairs Mean infant serum level of 0.16 meq/L (range 0.09–0.25)
In four infants: transient elevations of TSH, blood urea nitrogen and creatinine
Bogen et al. (2012) Case series 3 mothers with 4 infants Infant lithium levels ranged from 10 to 17% of maternal levels at 1 month postpartum
Frew (2015) Case report 1 mother–infant pair Infant/maternal serum lithium concentration ratio of 0.58. No adverse events
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mother–infant pairs. In one pair lithium serum levels of 
the infant achieved 17–20% of the maternal serum level 
while in the other infant this was calculated to be 50%. 
No adverse effects were observed in the lithium exposed 
infants. Viguera et  al. measured lithium levels in breast 
milk, maternal serum and infant serum in ten mother 
child pairs from eight to 27 weeks postpartum (Viguera 
et  al. 2007). Based on these measurements it was esti-
mated that infant lithium levels in serum were about one 
quarter of the lithium levels in serum of the mother. This 
estimation was lower than previous reports (Frew 2015; 
Schou and Amdisen 1973; Moretti et  al. 2003). Lithium 
exposure through breastmilk was generally well tolerated 
by the infants in this study although one infant devel-
oped elevated levels of TSH which, normalised after the 
mother discontinued lithium treatment. Three other 
infants showed transient elevations in blood urea nitro-
gen and creatinine levels. In summary, there is a lack of 
sufficient information on infant lithium levels and the 
consequences of lithium exposure through breast milk. 
Due to the lack of information and the possible nephro-
toxic effects of lithium in infants, in combination with the 
vulnerability of the developing neonatal kidneys and the 
risk of dehydration associated with the neonatal period, 
breastfeeding while on lithium treatment is discouraged 
in many national guidelines and individual centers world-
wide (Galbally et al. 2018).
Lithium use postpartum
• When lithium is discontinued during pregnancy, lith-
ium should be restarted immediately after delivery 
and is an effective strategy for relapse prevention in 
the immediate postpartum.
• For women with an isolated episode of postpartum 
psychosis or mania in history lithium prophylaxis 
immediately after delivery is effective for relapse pre-
vention, there is no need to use lithium during preg-
nancy.
• Consider a high target therapeutic lithium level 
immediately after delivery and during the first month 
postpartum to optimize relapse prevention (e.g., 0.8–
1.0 mmol/L).
• Obtain lithium blood levels twice weekly during the 
first 2 weeks postpartum.
• Breastfeeding while taking lithium is not recom-
mended.
Summary and discussion
The aim of this review was to provide a broad range of 
information and clinical guidance regarding lithium use 
during pregnancy and the postpartum period. Since 
it was our aim to give a broad overview of the litera-
ture from a clinical perspective we opted for a narrative 
review rather than a systematic review or meta-analysis. 
The clinical recommendations in this review article are 
suggestions based on the available scientific information 
and clinical experience of the authors. Readers should 
note that recommendations were not formulated within 
the context of a guideline procedure.
Women of childbearing age requiring mood stabilisa-
tion should be given the opportunity to weigh the risks 
and benefits of lithium treatment during pregnancy and 
the postpartum period, and to develop an individualised 
treatment plan together with their healthcare provid-
ers in a specialised centre (Bergink and Kushner 2014; 
Yonkers et  al. 2004). Antenatal care should take place 
in a multidisciplinary setting, with close collaboration 
between psychiatric and obstetric services. During preg-
nancy and the postpartum period women with bipolar 
disorder should be closely monitored. The possible risks 
for the unborn child, such as the risk of congenital mal-
formations need to be carefully weighed against the risk 
of maternal relapse. The pros and cons of discontinu-
ation of medication need to be compared with the pros 
and cons of continuing medication. In this context it is 
important to note that also relapse of bipolar disorder 
carries a fetal risk. High maternal stress but also high-risk 
behaviour, such as alcohol or drug use or lack of compli-
ance to antenatal care are associated with adverse fetal 
outcomes.
Switching to maintenance therapy with lamotrigine 
before conception should be considered as the efficacy 
of lamotrigine in prevention of postpartum relapse is not 
inferior to lithium (Wesseloo et al. 2017) and there are no 
risks of congenital malformations associated with its use 
(Patorno et al. 2017). However, the efficacy of lamotrigine 
in the prevention of postpartum episodes was established 
in a group of women with a high vulnerability to depres-
sive episodes and lamotrigine is not effective in the pre-
vention of mania. Moreover, the efficacy of lamotrigine 
in the prevention of relapse during pregnancy is not yet 
investigated. Maintenance therapy with second gen-
eration antipsychotics is an alternate treatment option 
(National Collaborating Centre for Mental H 2014). 
Importantly, the use of second generation antipsychotics 
during pregnancy is not associated with an increased risk 
of congenital malformations (Petersen et  al. 2016; Huy-
brechts et  al. 2016). However, a recent Medicaid study 
found an increased risk of gestational diabetes associated 
with the continuation of quetiapine and olanzapine dur-
ing pregnancy (Park et al. 2018) and there is uncertainty 
on the long-term impact on neurodevelopment (Poels 
et  al. 2018). Notably, the efficacy of second generation 
antipsychotics in relapse prevention during the perinatal 
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period is not yet properly investigated in women with 
bipolar disorder. Moreover, antipsychotics are known to 
be less effective than lithium in maintenance treatment 
for bipolar disorder outside the perinatal period (Geddes 
and Miklowitz 2013).
When providing advice to the individual patient, 
knowledge about past treatment efficacy should also be 
taken into account. In women with a history of severe 
bipolar episodes and a good effect on lithium therapy, 
continuation of lithium might be preferred in order to 
prevent relapse. When lithium therapy is continued dur-
ing pregnancy, regular antenatal visits are warranted for 
checking lithium blood levels, evaluation of fetal growth, 
and for monitoring signs of preterm labour. Detailed 
fetal anomaly scanning, including detailed fetal cardiac 
scanning should be offered at 20  weeks gestational age 
or maybe earlier in the future. Furthermore, evaluation 
of maternal thyroid (TSH and free T4) levels and kid-
ney function is recommended (Trimbos-instituut 2015). 
Delivery should take place in a specialised hospital where 
psychiatric and obstetric care for the mother is provided 
and neonatal evaluation and monitoring of the child can 
take place immediately after birth.
More investigations are required on the development 
of children exposed to lithium in utero as the studies that 
have been published so far provide insufficient informa-
tion to properly advise women.
We recommend against breastfeeding while on lithium 
treatment given both the paucity and the poor quality 
of the available clinical reports. However, we are aware 
of the differences in clinical recommendations between 
guidelines and authors. For instance, a recent systematic 
review by Pacchiarotti et  al. studied the same literature 
as reported in this review paper but they concluded that 
lithium levels in the infant were low and breastfeeding 
should be permitted through an individualized approach 
(Pacchiarotti et al. 2016). Clinicians that do recommend 
breastfeeding should publish their findings with com-
prehensive data on lithium levels in serum and breast 
milk, as well as infant outcomes including neurologi-
cal, renal and thyroid function. In this way more knowl-
edge will be available in order to develop evidence based 
recommendations.
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